139 related articles for article (PubMed ID: 37528674)
1. Expression and prognostic value of Cripto-1 in early non-small cell lung cancer.
Zhong J; Li L; Zhang Q; Zou J; Liu W; Xu CH
Clin Respir J; 2023 Dec; 17(12):1203-1208. PubMed ID: 37528674
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer.
Xu CH; Sheng ZH; Hu HD; Hao KK; Wang QB; Yu LK
Tumour Biol; 2014 Sep; 35(9):8673-8. PubMed ID: 24870591
[TBL] [Abstract][Full Text] [Related]
4. High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
Park KS; Moon YW; Raffeld M; Lee DH; Wang Y; Giaccone G
Lung Cancer; 2018 Feb; 116():38-45. PubMed ID: 29413049
[TBL] [Abstract][Full Text] [Related]
5. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
6. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of cripto-1 expression in non-small-cell lung cancer patients: a systematic review and meta-analysis.
Wei Y; Jiang J; Wang C; Zou H; Shen X; Jia W; Jin S; Zhang L; Hu J; Yang L; Pang L
Biomark Med; 2020 Mar; 14(4):317-329. PubMed ID: 32134335
[No Abstract] [Full Text] [Related]
8. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
[TBL] [Abstract][Full Text] [Related]
10. Expression of Cripto-1 predicts poor prognosis in stage I non-small cell lung cancer.
Xu C; Yuan Q; Hu H; Wang W; Zhang Q; Li L; Wang J; Yang R
J Cell Mol Med; 2020 Sep; 24(17):9705-9711. PubMed ID: 32697011
[TBL] [Abstract][Full Text] [Related]
11. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
[TBL] [Abstract][Full Text] [Related]
12. Serum cripto-1 as a clinical marker for lung cancer.
Xu CH; Cao L; Wei Y; Yu LK
Int J Biol Markers; 2015 Nov; 30(4):e369-73. PubMed ID: 26109366
[TBL] [Abstract][Full Text] [Related]
13. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
[TBL] [Abstract][Full Text] [Related]
14. Relationship between circulating lung-specific X protein messenger ribonucleic acid expression and micrometastasis and prognosis in patients with early-stage nonsmall cell lung cancer.
Cui Y; Wang W; Yao S; Qiu Z; Cong L
J Cancer Res Ther; 2020; 16(7):1641-1647. PubMed ID: 33565511
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle-related and expression-elevated protein in tumor overexpression is associated with proliferation behaviors and poor prognosis in non-small-cell lung cancer.
Li W; Zheng G; Xia J; Yang G; Sun J; Wang X; Wen M; Sun Y; Zhang Z; Jin F
Cancer Sci; 2018 Apr; 109(4):1012-1023. PubMed ID: 29397041
[TBL] [Abstract][Full Text] [Related]
16. Cripto-1 expression and its prognostic value in human bladder cancer patients.
Wei B; Jin W; Ruan J; Xu Z; Zhou Y; Liang J; Cheng H; Jin K; Huang X; Lu P; Hu Q
Tumour Biol; 2015 Feb; 36(2):1105-13. PubMed ID: 25326807
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
18. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
[TBL] [Abstract][Full Text] [Related]
19. Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma.
Liu Q; Cui X; Yu X; Bian BS; Qian F; Hu XG; Ji CD; Yang L; Ren Y; Cui W; Zhang X; Zhang P; Wang JM; Cui YH; Bian XW
Mol Cancer; 2017 Apr; 16(1):81. PubMed ID: 28431580
[TBL] [Abstract][Full Text] [Related]
20. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
